A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast ca...

Full description

Bibliographic Details
Main Authors: Claudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro, Erick de la Cruz-Hernández, Alma Revilla-Vázquez, Alma Chávez-Blanco, Catalina Trejo-Becerril, Enrique Pérez-Cárdenas, Lucia Taja-Chayeb, Enrique Bargallo, Patricia Villarreal, Teresa Ramírez, Teresa Vela, Myrna Candelaria, Maria F Camargo, Elizabeth Robles, Alfonso Dueñas-González
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2006-12-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC1762324?pdf=render

Internet

http://europepmc.org/articles/PMC1762324?pdf=render

Similar Items